TL;DR
IL-17A is elevated 2-3× in insomnia (r=0.51 with PSQI), increases BBB permeability, and activates NF-κB to disrupt sleep circuits — a potential new biomarker and drug target.
Background
The link between inflammation and insomnia has been recognized for decades, but the specific molecular mediators have remained unclear. A comprehensive review from the University of Pavia published in Neurochemical Research identifies interleukin-17A as a potentially central mediator connecting immune dysregulation with chronic insomnia.
Key Findings
| Biomarker | Change in Insomnia | Correlation with PSQI |
|---|---|---|
| IL-17A | ↑ 2-3× | r=0.51 (strong) |
| IL-6 | ↑ 1.5× | r=0.35 (moderate) |
| TNF-α | ↑ 1.8× | r=0.38 (moderate) |
| CRP | ↑ 1.3× | r=0.20 (weak) |
Proposed Feedback Loop
Chronic insomnia → sympathetic activation → Th17 cell differentiation → IL-17A release → NF-κB activation in hypothalamus → disrupted GABAergic inhibition → worsened sleep
Clinical Implications
- IL-17A as novel serum biomarker for insomnia
- Existing IL-17A inhibitors (approved for psoriasis) may be repurposed
- Provides molecular explanation for stress-related insomnia
References
Frequently Asked Questions
Not yet. IL-17A shows promise as a biomarker but is not currently used clinically for insomnia diagnosis. Standard diagnosis remains clinical interview and sleep questionnaires.